金城医药：子公司申报的米拉贝隆原料药已通过GMP符合性检查

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice from the Beijing Drug Administration for its active pharmaceutical ingredient, Mirabegron, indicating successful compliance with the 2010 revised Good Manufacturing Practice standards [1] Group 1 - The inspection took place from December 11 to 15, 2023 [1] - The scope of the inspection covered the Mirabegron production line in the second workshop [1] - The inspection conclusion confirmed that the company met the relevant standards and appendix requirements [1]